Disclosures for "Phase 3 Clinical Study of IVIG for Efficacy and Safety in Patients with Autoimmune Encephalitis"
-
Mr. Sakamoto has received personal compensation for serving as an employee of Takeda Pharmaceutical Company Limited. Mr. Sakamoto has or had stock in Takeda Pharmaceutical Company Limited.
-
Dr. Kamei has nothing to disclose.
-
Prof. Tanaka has nothing to disclose.
-
Author has nothing to disclose
-
Dr. Hara has nothing to disclose.
-
Dr. Takahashi has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Synchronicity Pharma, Inc..
-
Dr. Yasui has nothing to disclose.
-
Dr. Nogawa has nothing to disclose.
-
Dr. Tokunaga has nothing to disclose.
-
Ms. Sasaki has received personal compensation for serving as an employee of Takeda Pharmaceutical Co. Ltd..
-
Dr. Kuga has nothing to disclose.
-
Dr. AY has received personal compensation for serving as an employee of Takeda.
-
Dr. Kanda has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Igaku-shoin Ltd..